Table 2.
Summary of retrospective manuscripts studying relationship of acute and late GI toxicity after prostate RT.
| Study name [citation] | Study design | Toxicity analysis time points | Toxicity grading system | Follow-up duration | Acute/late GI toxicity association | ||
|---|---|---|---|---|---|---|---|
| Acute end | Late start | Acute | Chronic | ||||
| Zilli et al. 2011 [23] | (i) IMRT 56 Gy in 4 Gy/F (n = 82) (ii) Neoadjuvant ± concurrent ADT (n = 12) |
6 W PTC | 6 M PTC | Acute RTOG | Late RTOG | Median 48 M (9–67 M) | No |
|
| |||||||
| Fiorica et al. 2010 [24] | (i) 78 Gy in 2 Gy/F, 3DCRT (n = 26) (ii) 78 Gy in 2 Gy/F + 6 M AST, 3DCRT (n = 81) |
TRT | 3 M PTC | WHO | SOMA | Median 35 M (9–88 M) | No |
|
| |||||||
| Ballar et al. 2009 [25] | 74 Gy in 2 Gy/F, 3DCRT (n = 104) | 6 M PTC | 6 M PTC | Acute RTOG | Late RTOG | Median 30 M (20–50 M) | No |
|
| |||||||
| Shu et al. 2001 [26] | 72.0 to 79.2 Gy, 3DCRT (n = 26) or IMRT (n = 18) | 6 M PTC | 6 M PTC | Acute RTOG | Late RTOG | Median 23.1 M (10–84.7 M) | No |
|
| |||||||
| Cahlon et al. 2008 [27] | (i) 86.4 Gy/48 F IMRT (n = 478) (ii) Some had adjuvant 3–6 M ADT |
90 D PTC | 90 D PTC | CTCAE V3 | CTCAE V3 | Media 53 M | Yes |
|
| |||||||
| Zelefsky et al. 2008 [28] | (i) 66–81 Gy, 1.8 Gy/F, 3DCRT or IMRT (n = 1571) (ii) Neoadjuvant ADT 3 M (n = 678) |
Assume 90 D PTC | Assume 90 D PTC | Assume CTCAE V3 |
CTCAE V3 | Median 8 Y (5–18 Y) | Yes |
|
| |||||||
| Jereczek-Fossa et al. 2010 [30] | (i) Definitive RT 76 Gy in 2 Gy/F, 3DCRT (n = 542) (ii) Postprostatectomy RT 70 Gy in 2 Gy/F, 3DCRT (n = 431) |
3 M PTC | 3 M PTC | Acute RTOG | Late RTOG | Median 25.2 M (1–129 M) | Yes |
|
| |||||||
| Liu et al. 2004 [22] | (i) Prospective database (n = 1192) (ii) 52.5–72 Gy in 20–36 F, conventional or 3DCRT (iii) Neoadjuvant (n = 459), median duration (5.1 M), concurrent (n = 285), adjuvant (n = 222), and median duration (11 M) |
Assume 90 D PTC | Assume 90 D PTC | Assume Acute RTOG | Modified RTOG/SOMA | Median 49 M (24–105 M) | Yes |
|
| |||||||
| Zelefsky et al. 2008 [29] | I25 implantation (110 Gy) followed in 2 M by 50.4 Gy of IMRT in 1.8 Gy/F (n = 127) | 90 D PTC | 90 D PTC | CTCAE | CTCAE | Median 30 M | No |
PTC = posttreatment completion, univariate (UV), multivariate (MV), androgen deprivation therapy (ADT), and TRT = throughout radiotherapy.
Acute RTOG = Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer acute morbidity rating scale.
Late RTOG = Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer late morbidity rating scale.
LENT = Late Effects Normal Tissue Task Force scale.
SOMA = Subjective, Objective, Management, and Analytic (SOMA) scales.
UCLA-PCI = University of California Loss Angeles Prostate Cancer Index.
RMH scale = Royal Marsden Hospital scale.
EPIC = Expanded Prostate Cancer Index Composite.
CTC v2 = Common Toxicity Criteria v2.0.
CTCAE V3 = Common Terminology Criteria for Adverse Events v3.0.
QLQ-C30 = EORTC QLQ-C30 quality of life questionnaire.
QLQ-PR25 = EORTC QLQ-PR25 quality of life questionnaire.
WHO = World Health Organization criteria.